References in periodicals archive ?
The incidence of Be1-2 expression in DLBCL varies between 24.0% and 77.0% (5-7), (10), (13), (20), (22), (24), (26), (27), (28).
It is important to identify, measure, and interpret the characteristics of alterations which have prognostic implications and influence in a DLBCL patient's survival.
We systematically reviewed the clinical and pathological features of all CD 20 negative DLBCL lymphoma patients diagnosed at our institution over the last 13 years.
The EDA-SVM method was applied firstly to the DLBCL data set.
Histologically, DLBCLs exhibit a diffuse effacement of the normal architecture by a submucosal, discohesive cellular infiltrate (figure 1).
Few studies have reported the use of immunohistochemical expression of CD10, Bcl-6, and/or MUM1 to classify cases of DLBCL into GC and non-GC subtypes in ARL patients.
Patients with DLBCL typically present with a rapidly enlarging mass in the neck or abdomen.
MTEM is conducting a Phase II monotherapy study of MT-3724 in relapsed/refractory DLBCL. This study has the potential to serve as a registration study.
Yescarta was the first CAR T cell therapy to be approved by the United States Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including DLBCL not otherwise specified, primary mediastinal large B-cell lymphoma, and high grade B-cell lymphoma and DLBCL arising from follicular lymphoma.
DLBCL was the most commonly histopathologic type (78.75%).
A 27-years old lactating female, diagnosed with DLBCL, underwent staging PET-CT scan.
Background: Prospective real-life data on the safety and effectiveness of rituximab in Chinese patients with diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL) are limited.
Acronyms browser ?
Full browser ?
- Dlala Brokerage and Investment Holding Co.
- DLC chip